Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Scribe Therapeutics has raised $25.0M in total funding. The most recent round was Grant. The last funding was announced in June 2026.
Scribe Therapeutics's investors include Andreessen Horowitz, RA Capital Management, Menlo Ventures, Wellington Management, Perceptive Advisors.
Scribe Therapeutics is headquartered in Alameda, United States.
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Scribe Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scribe Therapeutics — Funding & Investors." VCBacked, June 18, 2026, https://www.vcbacked.co/company/scribe-therapeutics-alameda-2. Accessed August 14, 2026.
VCBacked. (2026). Scribe Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/scribe-therapeutics-alameda-2
{{cite web |title=Scribe Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/scribe-therapeutics-alameda-2 |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated